Viemed Healthcare reported record third-quarter results characterized by double-digit revenue growth and significant sequential margin expansion. The company demonstrated improved operating leverage as net income surged 67.8% sequentially, while its diversified product mix reduced capital intensity.
Key Highlights
- Record net revenue reached $80.7 million, exceeding analyst estimates of $58.25 million and representing a 12.2% increase over the prior-year period.
- Adjusted EBITDA grew 24.4% sequentially to $17.1 million, with margins expanding 350 basis points to 21.1% of net revenue.
- High-growth segments led performance, with PAP therapy patients increasing 37.5% year-over-year to 43,861 and sleep resupply patients rising 22.1% to 40,918.
- Full-year 2026 revenue guidance was narrowed and raised at the low end to a range of $316 million to $320 million, while net capital expenditure guidance was lowered to 8.0%–9.0% of revenue.